CN111039942A - Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof - Google Patents
Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN111039942A CN111039942A CN201811191323.8A CN201811191323A CN111039942A CN 111039942 A CN111039942 A CN 111039942A CN 201811191323 A CN201811191323 A CN 201811191323A CN 111039942 A CN111039942 A CN 111039942A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Nitrogen-containing heterocyclic compound Chemical class 0.000 title claims abstract description 93
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 31
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 31
- 239000012453 solvate Substances 0.000 claims abstract description 31
- 230000003287 optical effect Effects 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 104
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 76
- 229910052717 sulfur Inorganic materials 0.000 claims description 65
- 239000002994 raw material Substances 0.000 claims description 63
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 47
- 229910052760 oxygen Inorganic materials 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 38
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 37
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 35
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 34
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 26
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 24
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 24
- 125000004450 alkenylene group Chemical group 0.000 claims description 24
- 125000004419 alkynylene group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 238000005859 coupling reaction Methods 0.000 claims description 20
- 238000003786 synthesis reaction Methods 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 150000001412 amines Chemical class 0.000 claims description 18
- 239000004327 boric acid Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 125000005549 heteroarylene group Chemical group 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 241000764238 Isis Species 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 12
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 12
- 239000010949 copper Substances 0.000 claims description 12
- 229910052802 copper Inorganic materials 0.000 claims description 12
- 150000004820 halides Chemical class 0.000 claims description 12
- 229910052763 palladium Inorganic materials 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims description 11
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 150000001299 aldehydes Chemical class 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 239000007818 Grignard reagent Substances 0.000 claims description 9
- 238000005577 Kumada cross-coupling reaction Methods 0.000 claims description 9
- 238000006619 Stille reaction Methods 0.000 claims description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 9
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- 150000004795 grignard reagents Chemical class 0.000 claims description 9
- 150000002576 ketones Chemical class 0.000 claims description 9
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 238000006268 reductive amination reaction Methods 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- 239000007821 HATU Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 claims description 3
- 239000002841 Lewis acid Substances 0.000 claims description 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000007098 aminolysis reaction Methods 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims description 3
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 claims description 2
- 238000006887 Ullmann reaction Methods 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 70
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 45
- 239000000543 intermediate Substances 0.000 description 41
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 34
- 238000001035 drying Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 238000004809 thin layer chromatography Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000010438 heat treatment Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000001816 cooling Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000005457 ice water Substances 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 229940125898 compound 5 Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910001413 alkali metal ion Inorganic materials 0.000 description 4
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- HXRVTZVVSGPFEC-BTJKTKAUSA-N (z)-but-2-enedioic acid;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C(O)C(O)C(O)=O HXRVTZVVSGPFEC-BTJKTKAUSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- SLBWENCMEQRYEG-UHFFFAOYSA-N 4-chloro-7-methylquinoline Chemical compound ClC1=CC=NC2=CC(C)=CC=C21 SLBWENCMEQRYEG-UHFFFAOYSA-N 0.000 description 2
- JPVTWKDGBWUNBQ-UHFFFAOYSA-N 7-methyl-1h-quinolin-4-one Chemical compound OC1=CC=NC2=CC(C)=CC=C21 JPVTWKDGBWUNBQ-UHFFFAOYSA-N 0.000 description 2
- RYVUQGFVQHXYKQ-UHFFFAOYSA-N 7-methyl-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound OC1=C(C(O)=O)C=NC2=CC(C)=CC=C21 RYVUQGFVQHXYKQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101001091423 Agaricus bisporus Polyphenol oxidase 2 Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 101000705994 Bombyx mori Phenoloxidase subunit 2 Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 101000606124 Margaritifera margaritifera Tyrosinase-like protein 2 Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 101000773106 Pinctada maxima Tyrosinase-like protein Proteins 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910001416 lithium ion Inorganic materials 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- ZMIAGLFTJCNFIR-UHFFFAOYSA-N 7-(bromomethyl)-4-chloroquinoline Chemical compound BrCC1=CC=C2C(Cl)=CC=NC2=C1 ZMIAGLFTJCNFIR-UHFFFAOYSA-N 0.000 description 1
- 101001091417 Agaricus bisporus Polyphenol oxidase 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101001125487 Bombyx mori Phenoloxidase subunit 1 Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101000606125 Margaritifera margaritifera Tyrosinase-like protein 1 Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- FUPNQLPVKOYIKK-UHFFFAOYSA-N [N+](=[N-])=C.C1CCCCC1 Chemical compound [N+](=[N-])=C.C1CCCCC1 FUPNQLPVKOYIKK-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- CXQGKOICHGQQMF-UHFFFAOYSA-N azido diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(ON=[N+]=[N-])OC1=CC=CC=C1 CXQGKOICHGQQMF-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- HVJJYOAPXBPQQV-UHFFFAOYSA-N ethyl 2-azidoacetate Chemical compound CCOC(=O)CN=[N+]=[N-] HVJJYOAPXBPQQV-UHFFFAOYSA-N 0.000 description 1
- OZOMNKPYBWQMAH-UHFFFAOYSA-N ethyl 7-methyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(C)C=CC2=C(O)C(C(=O)OCC)=CN=C21 OZOMNKPYBWQMAH-UHFFFAOYSA-N 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- FOULIPQFPOUDSG-UHFFFAOYSA-N methyl 3-(3-hydroxy-2-methylphenyl)-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C=2C(=C(O)C=CC=2)C)=C1C FOULIPQFPOUDSG-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000011453 reproductive organ cancer Diseases 0.000 description 1
- 208000028466 reproductive system neoplasm Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- QGXFDKHOSNJQKE-UHFFFAOYSA-N sulfuric acid;2,2,2-trifluoroacetic acid Chemical compound OS(O)(=O)=O.OC(=O)C(F)(F)F QGXFDKHOSNJQKE-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a nitrogen-containing heterocyclic compound, and a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound shown as a formula I, or an optical isomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof; wherein, the definition of each group is described in the specification. The compounds of formula I are useful for treating diseases associated with the PD-1/PD-L1 signaling pathway.
Description
Technical Field
The invention relates to the field of small molecule medicines, and particularly provides a small molecule compound which can be used for treating diseases related to a PD-1/PD-L1 signal pathway.
Background
The immune system plays a crucial role in controlling and curing many diseases, such as various cancers, diseases caused by viruses, and the like. Cancer cells often multiply rapidly by evading or suppressing the immune system in some way. One such way is to alter the expression of activating and inhibitory molecules on immune cells. Blocking the suppressive immune checkpoint, like PD-1, has proven to be a very effective method of suppressing cancer cells.
PD-1 is programmed cell death protein-1, also known as CD 279. It is expressed mainly in activated T cells and B cells and functions to inhibit the activation of cells, which is a normal homeostatic mechanism of the immune system, and PD-1 is a protective wall of our human body because excessive T/B cell activation causes autoimmune diseases. PD-1 is a type I transmembrane glycoprotein composed of 268 amino acids, and its structure mainly includes an outer immunoglobulin variable region, a hydrophobic transmembrane region, and an intracellular region. The intracellular region contains two phosphorylation sites, located in the immunoreceptor tyrosine inhibitory motif and immunoreceptor tyrosine switch motif, which also demonstrates that PD-1 is capable of back-regulating T cell receptor-mediated signaling. PD-1 has two ligands, PD-L1 and PD-L2, which differ in the manner of expression. PD-L1, which is up-regulated in many tumor cells, binds to PD-1 on T cells, inhibits T cell proliferation and activation, leaves T cells in an inactive state, and ultimately induces immune escape.
PD-1/PD-L1 exerts a reverse immunomodulatory effect. When PD-1 binds to PD-L1, tyrosine in the tyrosine-converting motif domain of the immune receptor of T cells can be phosphorylated, and the phosphorylated tyrosine can bind to phosphatase protein tyrosinase 2 and protein tyrosinase 1. This can block activation of extracellular signal-regulated kinase, and can block activation of phosphoinositide 3-kinase (PI3K) and serine-threonine protein kinase (Akt), thereby inhibiting T lymphocyte proliferation and secretion of related cytokines. While the PD-1/PD-L1 signal inhibits the activation and proliferation of T cells, the secretion of cytokines interleukin 2, interferon gamma and IL-10 can be realized. In addition, PD-1/PD-L1 signal has similar immune function to B cell, and when PD-1 binds to B cell antigen receptor, PD-1 cytoplasm region acts with tyrosinase containing protein tyrosinase 2 binding site, thereby preventing B cell activation.
PD-1/PD-L1-based immunotherapy is a new generation of immunotherapy that is of great interest. In recent years, a series of surprising research results prove that the PD-1/PD-L1 inhibitor has strong antitumor activity on various tumors. PD-1/PD-L1 antibody inhibitors that are currently marketed are Ninolumab from BMS, Lamboluzumab from Merck, and Atezolizumab from Roche. In addition to this, there are many studied PD-1/PD-L1 antibody inhibitors, including Cure Tech's Pidilizumab, GSK's AMP-224, and AstraZeneca's MEDI-4736.
Although tumor immunotherapy is considered as a new generation of revolution for targeted post-treatment cancer therapy. However, currently marketed and researched PD-1 single drug has its own defects, including injection administration, oral administration, instability in vivo, easy protease decomposition, easy immune cross reaction, difficult purification, high production cost, etc. Therefore, small molecule inhibitors of the PD-1/PD-L1 interaction are better candidates for tumor immunotherapy.
In view of the foregoing, there is a pressing need in the art to develop novel small molecule inhibitors of the PD-1/PD-L1 interaction.
Disclosure of Invention
The invention aims to provide a novel small molecule inhibitor of PD-1/PD-L1 interaction.
In a first aspect of the present invention, there is provided a compound represented by the following formula I, or an optical isomer, hydrate, solvate, or a pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1、L2and L3Each independently selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO2;
Y1、Y2、Y3Each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO or SO2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent;
Each independently selected from the group consisting of: substituted or unsubstituted C6-C10 arylene, or substituted or unsubstituted 5-12 membered (preferably 5-7 membered) heteroarylene having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclylene, substituted or unsubstituted 5-12 membered C5-C12 cycloalkylene; or the saidIs absent;
R1、R2、R3and R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstitutedC1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclyl having 1-4 heteroatoms, substituted or unsubstituted C6-C10 arylSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
In another preferred embodiment, theA bicyclic structure of 5-7 membered ring and 5-6 membered ring.
In another preferred embodiment, theIs a bicyclic structure selected from the group consisting of: a 6-membered and 6-membered ring, a 6-membered and 5-membered ring, a 5-membered and 6-membered ring.
wherein:
X1、X2、X3、X4、X5、X6each independently selected from the group consisting of: NH, N, CH2Or CH ═ CH;
In another preferred embodiment, theIs a ring-forming group selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, tetrazine, triazine, pyrrole, thiophene, furan, tetrazole, triazole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, oxadiazole, thiadiazole, naphthalene, indole, triazine, pyridine, thiophene, and thiophene,Indazole, quinoline, isoquinoline, morpholine, dihydropiperidine, thiomorpholine, piperidine, piperazine, tetrahydropyran, dihydropyran, pyrroline, tetrahydrothiophene, tetrahydrofuran, oxetane, thietane, azetidine, benzofuran, benzothiophene, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, benzisoxazole, benzotriazole.
in another preferred embodiment, theEach independently selected from the group consisting of: substituted or unsubstituted phenylene, substituted or unsubstituted 5-7 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted 5-7 membered heterocyclylene, substituted or unsubstituted C5-C7 cycloalkylene.
In another preferred embodiment, theEach independently a ring-forming group selected from the group consisting of: benzene, pyridine, pyrimidine, pyridazine, tetrazine, triazine, pyrrole, thiophene, furan, tetrazole, triazole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, oxadiazole, thiadiazole, naphthalene, indole, indazole, quinoline, isoquinoline, morpholine, dihydropiperidine, thiomorpholine, piperidine, piperazine, tetrahydropyran, dihydropyran, pyrroline, tetrahydrothiophene, tetrahydrofuran, oxetane, thietane, azapineCyclobutane, benzofuran, benzothiophene, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, benzisoxazole, benzotriazole.
In another preferred embodiment, theEach independently a ring-forming group selected from the group consisting of:
in another preferred embodiment, theEach independently is a structure represented by the following formula (III):
wherein:
Z1a、Z2a、Z3a、Z4aeach independently selected from the group consisting of: n, CH are provided.
In another preferred embodiment, the structure of formula II or formula III may be substituted or unsubstituted.
In another preferred embodiment, R is2Selected from the group consisting of: C1-C6 alkyl, CN.
wherein, L is4Selected from the group consisting of: substituted or unsubstituted C1-C4 alkylene, -S-, -O-, -NRa-, -S (O) -, -S (O)2-; preferably a substituted or unsubstituted C1-C4 alkylene group;
selected from the group consisting of: a substituted or unsubstituted 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; preferably, saidIs a 5-7 membered nitrogen containing heterocyclic group;
R5selected from the group consisting of: substituted or unsubstituted C1-C6 alkyl, -CN, hydroxy, amino, carboxy; wherein the substituents are selected from the group consisting of: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy.
In another preferred embodiment, R is4Selected from the group consisting of: -O (substituted or unsubstituted C1-C6 alkyl), -O (CH)2)n- (substituted or unsubstituted 5-to 7-membered heteroaryl having 1 to 3 heteroatoms selected from N, S and O).
In another preferred embodiment, the compound of formula I is selected from a compound of formula Ia, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC(s) ((s))O)NH-、Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted having 1 to 4 heteroatoms5-to 12-membered heterocyclic group of (a), substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
Preferably, the compound is selected from compounds 1-125.
In another preferred embodiment, the compound of formula I is selected from compounds of formula Ib, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstitutedC of (A)3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkyleneA substituted or unsubstituted 5-10 membered heterocyclylene group having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino)) Substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted 5-to 12-membered heterocyclic group having 1 to 4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
Preferably, the compound is selected from compounds 126-202.
In another preferred embodiment, the compound of formula I is selected from compounds of formula Ic, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstitutedunsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of:H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted 5-to 12-membered heterocyclyl having 1 to 4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
Preferably, the compound is selected from the group consisting of compounds 203-313.
In another preferred embodiment, the compound of formula I is selected from the group consisting of formulae Id-1 and Id-2, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1and L3Each independently selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2and Z3Each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1and Y2Each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2And R3Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstitutedC6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclyl having 1-4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
Preferably, the compound is selected from the group consisting of compounds 314 and 355.
In another preferred embodiment, the compound of formula I is selected from a compound of formula Ie, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or notSubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstitutedUnsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms
Substituted or unsubstituted 5-12 membered heterocyclic group having 1-4 hetero atoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
Preferably, the compound is selected from the group consisting of 356-360.
In another preferred embodiment, the pharmaceutically acceptable salts include salts formed in combination with inorganic acids, organic acids, alkali metal ions, alkaline earth metal ions, or organic bases capable of providing physiologically acceptable cations, as well as ammonium salts.
In another preferred embodiment, the inorganic acid is selected from hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; the organic acid is selected from methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, lycic acid, tartaric acid maleate, fumaric acid, citric acid or lactic acid; the alkali metal ions are selected from lithium ions, sodium ions and potassium ions; the alkaline earth metal ions are selected from calcium ions and magnesium ions; the organic base capable of providing a physiologically acceptable cation is selected from methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris (2-hydroxyethyl) amine.
In a second aspect of the invention, there is provided a process for the preparation of a compound of formula I as described in the first aspect of the invention, said process comprising a step selected from the group consisting of those depicted in schemes 1,2 or 3:
synthesis scheme 1
(e) Taking halide 1-1 and appropriate coupling reagent 1-2 (such as boric acid, boric acid ester, tin reagent or Grignard reagent) as basic raw materials, and obtaining an intermediate compound 1-3 through coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(f) taking the intermediate 1-3 as a raw material, and reacting with carboxylic acid 1-4 under the action of a condensing agent (such as HATU, EDCI or HBTU) to obtain an amide intermediate 1-5;
(g) taking the intermediate 1-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 1-6;
(h) taking the intermediate 1-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
synthesis scheme 2:
(e) taking carboxylic ester 2-1 as a raw material, and carrying out an aminolysis reaction with amine 2-2 under the catalysis of Lewis acid to obtain an intermediate compound 2-3;
(f) taking the intermediate 2-3 and a proper coupling reagent 2-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 2-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(g) taking the intermediate 2-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 2-6;
(h) taking the intermediate 2-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
synthesis scheme 3:
(e) using carboxylic ester 3-1 as a raw material, and carrying out Buchwald-Hartwig coupling or Ullmann coupling with amine 3-2 under the catalysis of palladium or copper to obtain an intermediate compound 3-3;
(f) taking the intermediate 3-3 and a proper coupling reagent 3-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 3-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(g) taking the intermediate 3-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 3-6;
(h) taking the intermediate 3-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising (1) a compound according to the first aspect of the present invention or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof; (2) a pharmaceutically acceptable carrier.
In a fourth aspect of the present invention, there is provided a use of the compound according to the first aspect of the present invention or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or the pharmaceutical composition according to the second aspect of the present invention, for the preparation of a pharmaceutical composition for the prevention and/or treatment of a disease associated with an activity or an expression amount of PD-1/PD-L1.
In a fifth aspect of the invention, there is provided a PD-1/PD-L1 inhibitor, said inhibitor comprising a compound according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
In another preferred embodiment, the pharmaceutical composition is used for treating a disease selected from the group consisting of: cancer, infectious disease, autoimmune disease.
In another preferred embodiment, the cancer is selected from skin cancer, lung cancer, urinary tumor, hematological tumor, breast cancer, glioma, digestive tumor, reproductive tumor, lymphoma, nervous system tumor, brain tumor, head and neck cancer.
In another preferred embodiment, the infectious disease is selected from bacterial infection and viral infection.
In another preferred embodiment, the autoimmune disease is selected from organ-specific autoimmune disease, systemic autoimmune disease.
In another preferred embodiment, the organ-specific autoimmune disease comprises chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, goodpasture's syndrome, primary biliary cirrhosis, multiple sclerosis, acute idiopathic polyneuritis.
In another preferred embodiment, the systemic autoimmune disease comprises rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia.
In a sixth aspect of the present invention, there is provided a method for inhibiting the PD-1/PD-L1 interaction in vitro, comprising the steps of: contacting a compound according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, with PD-L1 protein.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Detailed Description
The inventor has extensively and intensively studied and found a PD-1/PD-L1 interaction inhibitor with excellent inhibitory effect. On this basis, the inventors have completed the present invention.
Definition of
As used herein, the term "alkyl" includes straight or branched chain alkyl groups. E.g. C1-C8Alkyl represents a straight or branched chain alkyl group having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.
As used herein, the term "alkenyl" includes straight or branched chain alkenyl groups. E.g. C2-C6Alkenyl means a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
As used herein, the term "alkynyl" includes straight or branched chain alkynyl groups. E.g. C2-C6Alkynyl means a straight-chain or branched alkyne having from 2 to 6 carbon atomsAnd an alkyl group such as an ethynyl group, propynyl group, butynyl group, or the like.
As used herein, the term "C3-C10Cycloalkyl "refers to cycloalkyl groups having 3 to 10 carbon atoms. It may be a single ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. It may also be in the form of a double ring, for example a bridged or spiro ring.
As used herein, the term "C1-C8Alkylamino "is defined as being substituted by C1-C8The amino group substituted by the alkyl can be mono-substituted or di-substituted; for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di-tert-butylamino and the like.
As used herein, the term "C1-C8Alkoxy "means a straight or branched chain alkoxy group having 1 to 8 carbon atoms; for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy and the like.
As used herein, the term "3-10 membered heterocycloalkyl having 1-3 heteroatoms selected from the group consisting of N, S and O" refers to a saturated or partially saturated cyclic group having 3-10 atoms and wherein 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be monocyclic or may be in the form of a double ring, for example a bridged or spiro ring. Specific examples may be oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, and the like.
As used herein, the term "C6-C10Aryl "means an aryl group having 6 to 10 carbon atoms, for example, phenyl or naphthyl and the like.
As used herein, the term "5-10 membered heteroaryl having 1-3 heteroatoms selected from the group consisting of N, S and O" refers to a cyclic aromatic group having 5-10 atoms and wherein 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be a single ring or a condensed ring form. Specific examples may be pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3) -triazolyl and (1,2,4) -triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl and the like.
Unless specifically stated to be "substituted or unsubstituted", the groups of the present invention may be substituted with a substituent selected from the group consisting of: halogen, nitrile group, nitro group, hydroxyl group, amino group, C1-C6Alkyl-amino, C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Alkoxy, halo C1-C6Alkyl, halo C2-C6Alkenyl, halo C2-C6Alkynyl, halo C1-C6Alkoxy, allyl, benzyl, C6-C12Aryl radical, C1-C6alkoxy-C1-C6Alkyl radical, C1-C6Alkoxy-carbonyl, phenoxycarbonyl, C2-C6Alkynyl-carbonyl, C2-C6Alkenyl-carbonyl, C3-C6Cycloalkyl-carbonyl, C1-C6Alkyl-sulfonyl, and the like.
As used herein, "halogen" or "halogen atom" refers to F, Cl, Br, and I. More preferably, the halogen or halogen atom is selected from F, Cl and Br. "halogenated" means substituted with an atom selected from F, Cl, Br, and I.
Unless otherwise specified, the structural formulae depicted herein are intended to include all isomeric forms (e.g., enantiomers, diastereomers and geometric isomers (or conformational isomers)): for example, R, S configuration containing an asymmetric center, (Z), (E) isomers of double bonds, and the like. Thus, individual stereochemical isomers of the compounds of the present invention or mixtures of enantiomers, diastereomers or geometric isomers (or conformers) thereof are within the scope of the present invention.
As used herein, the term "tautomer" means that structural isomers having different energies may exceed the low energy barrier, thereby converting with each other. For example, proton tautomers (i.e., proton transmutations) include interconversion by proton shift, such as 1H-indazoles and 2H-indazoles. Valence tautomers include interconversion by recombination of some of the bonding electrons.
As used herein, the term "solvate" refers to a complex of a compound of the present invention coordinated to solvent molecules in a specific ratio.
As used herein, the term "hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.
Active ingredient
As used herein, "compounds of the invention" refers to compounds of formula I, and also includes various crystalline forms, pharmaceutically acceptable salts, hydrates, or solvates of the compounds of formula I.
Preferred compounds of the present invention include compounds 1-360 (including various classes of R configuration and/or S configuration stereoisomers of each compound, and/or E-/Z-cis-trans isomers).
In another preferred embodiment, the pharmaceutically acceptable salts include salts formed in combination with inorganic acids, organic acids, alkali metal ions, alkaline earth metal ions, or organic bases capable of providing physiologically acceptable cations, as well as ammonium salts.
In another preferred embodiment, the inorganic acid is selected from hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; the organic acid is selected from methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, lycic acid, tartaric acid maleate, fumaric acid, citric acid or lactic acid; the alkali metal ions are selected from lithium ions, sodium ions and potassium ions; the alkaline earth metal ions are selected from calcium ions and magnesium ions; the organic base capable of providing a physiologically acceptable cation is selected from methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris (2-hydroxyethyl) amine.
All such salts within the scope of the present invention may be prepared by conventional methods. During the preparation of the compounds of formula I and solvates and salts thereof, different crystallization conditions may occur as polycrystals or co-crystals.
Preparation of Compounds of formula I
For the preparation of the compounds of the general formula I according to the invention, the preparation of the compounds of the general formula I according to the invention can be obtained by the following synthetic route, depending on the structure of the general formula I.
(a) Taking halide 1-1 and appropriate coupling reagent 1-2 (such as boric acid, boric acid ester, tin reagent or Grignard reagent) as basic raw materials, and obtaining an intermediate compound 1-3 through coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(b) taking the intermediate 1-3 as a raw material, and reacting with carboxylic acid 1-4 under the action of a condensing agent (such as HATU, EDCI or HBTU) to obtain an amide intermediate 1-5;
(c) taking the intermediate 1-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 1-6;
(d) taking the intermediate 1-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
the second method comprises the following steps:
(a) taking carboxylic ester 2-1 as a raw material, and carrying out an aminolysis reaction with amine 2-2 under the catalysis of Lewis acid to obtain an intermediate compound 2-3;
(b) taking the intermediate 2-3 and a proper coupling reagent 2-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 2-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(c) taking the intermediate 2-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 2-6;
(d) taking the intermediate 2-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
the method 3 comprises the following steps:
(a) using carboxylic ester 3-1 as a raw material, and carrying out Buchwald-Hartwig coupling or Ullman coupling with amine 3-2 under the catalysis of palladium or copper to obtain an intermediate compound 3-3;
(b) taking the intermediate 3-3 and a proper coupling reagent 3-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 3-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(c) taking the intermediate 3-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 3-6;
(d) taking the intermediate 3-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
In addition, the starting materials and intermediates in the above reactions are readily available, and the reactions in each step can be readily synthesized according to reported literature or by conventional methods in organic synthesis to those skilled in the art. The compounds of formula I may exist in the form of solvates or non-solvates, and crystallization using different solvents may give different solvates.
Pharmaceutical compositions and methods of administration
The compound of the present invention and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compound of the present invention as a main active ingredient can be used for preventing and/or treating (stabilizing, alleviating or curing) diseases (e.g., cancer, infectious diseases, autoimmune diseases) associated with the PD-1/PD-L1 interaction, because the compound of the present invention has excellent inhibitory activity of the PD-1/PD-L1 interaction.
The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention in combination with a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-200mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), and the like ) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous).
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds (e.g., other anti-cancer agents).
When administered in combination, the pharmaceutical composition further comprises one or more (2, 3, 4, or more) other pharmaceutically acceptable compounds. One or more (2, 3, 4, or more) of the other pharmaceutically acceptable compounds may be used simultaneously, separately or sequentially with the compounds of the invention for the prevention and/or treatment of a disease associated with the PD-1/PD-L1 interaction.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 20 to 500 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
The main advantages of the invention include:
(1) the compound has high inhibitory activity on the interaction of PD-1/PD-L1, has strong binding capacity with PD-L1 protein, and has the capacity of relieving the inhibition of IFN gamma by PD-L1.
(2) The compound of the invention has better solubility; the toxicity to normal cells is very low and can therefore be applied to the treated subject over a wide dose range.
(3) Compared with the prior art, the compound of the invention has better solubility and good drug forming property, and the compound of the invention has good bioavailability in vivo experiments, and in addition, compared with the prior art, the compound of the invention can be easily prepared into pharmaceutically acceptable salts, thereby being beneficial to further preparation.
(4) The in vivo efficacy research shows that the compound can obviously inhibit the growth of subcutaneous tumors no matter on the tumor volume or the tumor weight, and can obviously increase the number of lymphocytes in the blood and the spleen of a mouse.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
The test materials and reagents used in the following examples are commercially available without specific reference.
General materials and test methods:
the instruments and materials involved in the examples are described below:
the NMR spectrum was obtained by analysis with a Bruker AV-400(400MHz) NMR spectrometer.
Chemical shifts are reported in ppm units using tetramethylsilane as an internal standard (CDC 1)3Delta 7.26 ppm). The data reported are the chemical shifts and their split and coupling constants (s: singlet; d: doublet; t: triplet; q: quartet; br: broad; m: multiplet).
Mass spectrometry data were analyzed using a liquid mass spectrometer from the Finnigen advanced LCQ company (Finnigan LCQ Advantage), all reactions operated under anhydrous and oxygen-free conditions under dry argon protection, except for other requirements. The solid organometallic compound was stored in an argon protected dry box.
The tetrahydrofuran and the diethyl ether are obtained by distillation, and metal sodium and benzophenone are added into the tetrahydrofuran and the diethyl ether during the distillation. Methylene chloride, pentane and hexane were treated with calcium hydride.
The special raw materials and intermediates involved in the present invention are provided by custom-made processing of Tianjin Changsen pharmaceutical Co., Ltd, and all other chemical reagents are purchased from reagent suppliers such as Shanghai chemical reagent company, Aldrich company (Aldrich), Acros company (Acros). If the intermediates or products needed by the reaction in the synthesis process are not enough for the next experiment, the synthesis is repeated for a plurality of times until the intermediates or products are enough.
The raw materials and reagents related to the invention can be obtained by commercial or customized processing and purchase except for special instructions.
The compounds of the invention may contain one or more asymmetric centres and so the series of compounds may be in racemic or single enantiomeric form. The compound prepared by the invention is a heterocyclic compound with the purity higher than 95 percent, and the structural representation of each final product is respectively represented by MS or/and hydrogen spectrum nuclear magnetic resonance (1H NMR) analysis. The synthesis of the various compounds and intermediates of the invention is illustrated by the examples below.
Example 1: synthesis of (R) -3 ' - ((7- ((3-hydroxypyrrol-1-yl) methyl) quinolin-4-yl) oxy) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3-carboxylic acid
Step 1:
diethyl ethoxymethylenemalonate (150mL, 749mmol) and m-toluidine (80mL, 738mmol) were placed in a flask, and the mixture was heated at 110 ℃ for 1 hour. The reaction mixture was cooled to room temperature. The flask was placed in a refrigerator and the precipitated solid was collected and washed with hexane to give the product as a white solid (120g, 58% yield).
1H NMR(400MHz,CDCl3)δ10.99(d,J=13.8Hz,1H),8.54(d,J=13.8Hz,1H),7.30–7.25(m,1H),7.02–6.92(m,3H),4.37–4.22(m,4H),2.38(s,3H),1.37(dt,J=19.5,7.1Hz,6H).ESI m/z 278.2(M+H).
Step 2:
diethyl 2- ((m-tolylamino) methylene) malonate (148g, 534mmol) was suspended in diphenyl ether (200mL) and the mixture was refluxed for 45 minutes. The solution was allowed to cool to room temperature and the solid formed was collected and bubbled with hexane to give the product as a white solid (26.7g, 22% yield).
1H NMR(400MHz,DMSO-d6)δ12.19(s,1H),8.49(d,J=6.5Hz,1H),8.04(d,J=8.2Hz,1H),7.38(s,1H),7.24(dd,J=8.3,1.5Hz,1H),4.21(q,J=7.1Hz,2H),2.80(s,1H),2.44(s,3H),1.28(t,J=7.1Hz,3H).ESI m/z 232.0(M+H).
And step 3:
ethyl-4-hydroxy-7-methylquinoline-3-carboxylate (43g, 187mmol) was added to 5M sodium hydroxide (200mL) and heated at reflux for 1 h. The mixture was cooled to room temperature and acidified to pH 4 by addition of 2M HCl. The solid formed was collected, washed with water and dried to give 4-hydroxy-7-methylquinoline-3-carboxylic acid as a white solid (37.8g, 90% yield).
ESI m/z 204.0(M+H).
And 4, step 4:
4-hydroxy-7-methylquinoline-3-carboxylic acid (35g, 172mmol) was suspended in diphenyl ether (100 mL). The mixture was refluxed for 1.5 hours and then cooled to room temperature. The precipitated solid was collected and washed with hexane to give 7-methylquinolin-4-ol as a white solid (16.8g, 62% yield).
ESI m/z 160.0(M+H).
And 5:
to a solution of 7-methylquinolin-4-ol (26g, 162mmol) in chloroform (150mL) at 0 deg.C was added phosphorus oxychloride (50 mL). The mixture was then refluxed for 3 hours, then cooled to room temperature and neutralized with 2M NaOH. The resulting solid was collected, washed with water and dried to give 4-chloro-7-methylquinoline as a white solid (17g, 59% yield).
1H NMR(400MHz,CDCl3)δ8.76(d,J=4.8Hz,1H),8.14(d,J=8.5Hz,1H),7.97–7.91(m,1H),7.50(dd,J=8.6,1.7Hz,1H),7.45(d,J=4.8Hz,1H),2.61(d,J=0.9Hz,3H).ESIm/z 178.0(M+H).
Step 6:
to CCl of 4-chloro-7-methylquinoline (7g, 39mmol)4To the solution (60mL) was added NBS (8g, 45mmol) and benzoyl peroxide (0.8g, 3.3 mmol). The solution was refluxed for 5 hours. After completion of the reaction, the solvent was evaporated and the resulting residue was purified by flash chromatography to give the product as a white solid (2.48g, 25% yield).
1H NMR(400MHz,CDCl3)δ8.82(d,J=4.7Hz,1H),8.27(d,J=8.7Hz,1H),8.15–8.11(m,1H),7.72(dd,J=8.7,1.8Hz,1H),7.53(d,J=4.7Hz,1H),4.71(s,2H).ESI m/z 258.0(M+H).
And 7:
(R) -pyrrolidin-3-ol (957mg, 11mmol) was added to 7- (bromomethyl) -4-chloroquinoline (2.56g, 10mmol) and Et 3N (2.16ml, 15mmol) in dichloromethane (20 ml). After stirring at room temperature for 4 hours, the solvent was removed and the resulting residue was purified by flash chromatography to give the product (2.35g, 90% yield). ESI M/z 263.0(M + H).
Step 8
To a solution of methyl 3 ' -hydroxy-2, 2 ' -dimethyl- [1,1 ' -biphenyl ] -3-carboxylate (256mg, 1mmol) in DMF (3mL) at 0 deg.C was added NaH (80mg, 2 mmol). The mixture was stirred at this temperature for 30 minutes, then (R) -1- ((4-chloroquinolin-7-yl) methyl) pyrrolidin-3-ol (262mg, 1mmol) was added. The reaction was heated at 120 ℃ overnight and then cooled to room temperature. The mixture was purified by prep-HPLC to give the product (79mg, 17% yield).
ESI m/z 469.2(M+H).
Example 2: 5- (((trans) -4- (methoxycarbonyl) cyclohexyl) methyl) -1-methyl-4, 5,6, 7-tetrahydro-1H-imidazo [4,5-c ] pyridine-2-carboxylic acid
The synthetic route is as follows:
step 1:
dissolving the compound 1(474mg, 2mmol) in 10mL of anhydrous THF under the protection of nitrogen, cooling to-78 ℃, slowly dropwise adding 1mL of 2.5M butyl lithium n-hexane solution, continuing to stir for 30min after the dropwise adding is finished, dropwise adding benzyl chloroformate (511mg, 3mmol), continuing to stir for 1h after the dropwise adding is finished, heating to room temperature, quenching by using saturated sodium bicarbonate solution, performing post-treatment and performing column chromatography to obtain the product.
Step 2:
the compound 2(300mg) was added to 10mL of 4N HCl/dioxane solution, stirred at room temperature for 1h, TLC followed the disappearance of the starting material, and concentrated under reduced pressure to give a solid which was used directly in the next reaction.
And step 3:
under the protection of argon, DMSO (3.12g, 40mmol) is added into DCM (50ml), after stirring for 10min, the mixture is cooled to-78 ℃, oxalyl chloride (2.54g, 20mmol) is added dropwise, after the addition is finished, the mixture is stirred for 10min, then a DCM solution of a compound 4(3.44g, 20mmol) is added dropwise, after stirring for 10min, triethylamine (5.26g, 52mmol) is slowly added dropwise, after stirring for 10min, the mixture is moved to room temperature and is stirred for about 30min, DCM and water are added for quenching, extraction, drying and concentration are carried out to obtain an oily liquid.
And 4, step 4:
under the protection of argon, hydrochloride (31mg, 0.1mmol) of compound 3, compound 5(22.3mg, 0.13mmol) and potassium carbonate (13.9mg, 0.1mmol) were added to a solution of DCM (1.0ml), placed in an ice bath and stirred for 30min to add NaBH (OAc) in portions3(49.1mg, 0.23mmol) and then allowed to warm to room temperature and stirred overnight. Conversion to product was detected by TLC and LCMS.
And 5:
compound 6(100mg, 0.24mmol) was dissolved in THF (5ml), 10% Pd/C (100mg) was added, hydrogenation was carried out at normal pressure for 5 hours, filtration and concentration of the solvent gave a solid.
LCMS found 336[M+H]+
Example 3: synthesis of 5- (2- ((tert-butyldiphenylsilyl) oxy) ethyl) -1-methyl-4-oxo-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxylic acid
The synthetic route is as follows:
step 1:
adding raw material aldehyde 1(25g, 1.0eq) into methanol (250ml), protecting with argon, cooling (the internal temperature is-10 ℃ to-15 ℃) and adding azide raw material 2(57g, 2.5eq), wherein the system is clear and does not heat up; dropwise adding 30% sodium methoxide methanol solution (81g, 2.5eq) to control the temperature at minus 12 +/-2 ℃, and maintaining the temperature for 1 h; overnight at 0 ℃; the system was cloudy and the viscosity gradually increased. And (3) treatment: pouring the reaction solution into a mixed system of ice water and ammonium chloride solid, stirring for 30 minutes, filtering, adding water into the solid, rinsing for 3 times, and pumping by an oil pump to obtain 58g of brown yellow solid (quantitative yield), and directly putting the brown yellow solid into the next step.
1H NMR(400MHz,CDCl3)δ8.49(dd,J=7.6,1.9Hz,1H),8.11(dd,J=5.0,1.9Hz,1H),7.25(d,J=11.9Hz,1H),6.93(dd,J=7.7,4.9Hz,1H),3.99(s,3H),3.92(s,3H).
LCMS found 208[M+H-N2]+
Step 2:
adding the raw material 3(26g) into o-dichlorobenzene (500ml), and reacting for 1 hour at 145 ℃ by external bath; and (3) treatment: cooling to-10 deg.C, stirring for 10min, filtering, rinsing the solid with n-heptane, and drying to obtain light yellow solid 7g (yield: 50%)
1H NMR(400MHz,DMSO-d6)δ12.36(s,1H),7.83(d,J=5.9Hz,1H),7.13(d,J=2.0Hz,1H),7.02(d,J=5.9Hz,1H),3.97(s,3H),3.87(s,3H).
LCMS:found 207[M+H]+
And step 3:
adding the raw material 4(6.8g, 1.0eq) into DMAc (70ml), dissolving to be clear, adding potassium carbonate (9.12g, 2.0eq), dropwise adding methyl iodide (7g, 1.5eq), and reacting at room temperature overnight; and (3) treatment: water (50ml), ammonia (20ml), EA (100ml x 3) was added for extraction, column: elution with ethyl acetate/n-heptane 15/85 gave 6.05g of a yellow solid (yield: 83.4%).
1H NMR(400MHz,CDCl3)δ7.94(d,J=6.1Hz,1H),7.39(d,J=0.9Hz,1H),7.26(s,1H),6.97–6.83(m,1H),4.11(s,3H),4.04(s,3H),3.91(s,3H).
LCMS:found 221[M+H]+
And 4, step 4:
adding 5(5g, 1.0eq) of raw material into acetic acid (82g, 30eq), adding 47% of hydrobromic acid aqueous solution (55g, 30eq), dissolving, and heating to 95 ℃ for reaction for 2 hours; and (3) treatment: concentration to give 9g (yield: quantitative) of pale yellow solid, which was directly fed to the next step.
LCMS:found 193[M+H]+
And 5:
adding 6(4.36g, 1.0eq) of raw material into methanol (90ml) for insolubilization, adding concentrated sulfuric acid (5g, 1.0eq), and carrying out reflux reaction at 85 ℃ in an external bath overnight; and (3) treatment: under ice bath, 70ml of saturated sodium bicarbonate is added dropwise, the pH value is 7-8, a solid is precipitated, the solid is filtered, rinsed with water and dried to obtain 4.43g of a white solid (yield: 94.8%).
1H NMR(400MHz,DMSO-d6)δ11.02(s,1H),7.24(s,1H),7.20(t,J=6.5Hz,1H),6.58(d,J=7.4Hz,1H),3.93(s,3H),3.81(s,3H).
LCMS found:207[M+H]+
Step 6:
adding a raw material 7(4.2g, 1.0eq) into DMAc (50ml), protecting with argon, adding cesium carbonate (13.3g, 2.0eq), adding a silanol raw material 8(9.62g, 1.3eq), and reacting at room temperature overnight; and (3) treatment: adding water (100ml) and 1M hydrochloric acid (80ml) to adjust the pH value to 5-6; EA extraction 3 times, column chromatography: 20% EA/n-heptane rinse, concentrate to give 4.5g of white solid, yield: 45.4 percent.
1H NMR(400MHz,DMSO-d6)δ7.54(d,J=7.5Hz,1H),7.45(d,J=7.3Hz,4H),7.39(t,J=7.5Hz,2H),7.32–7.23(m,5H),6.66(d,J=7.5Hz,1H),4.13(t,J=5.0Hz,2H),3.95(s,3H),3.86(t,J=5.0Hz,2H),3.83(s,3H),0.93(s,9H).
LCMS found:489[M+H]+。
Step 7
Taking raw material 9(4.5g,1.0eq) and adding into THF (45ml), adding water (45ml) after dissolving, adding lithium hydroxide hydrate (0.97g,2.5eq) and reacting for 2 hours; and (3) treatment: 1M hydrochloric acid (50ml) and water (50ml) were added to precipitate a white solid, which was stirred for 30 minutes, the solid was filtered and dried to obtain 4.05g of 5- (2- ((tert-butyldiphenylsilyl) oxy) ethyl) -1-methyl-4-oxy-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxylic acid as a white solid, yield: 92.6 percent.
1H NMR(400MHz,DMSO-d6)δ12.82(s,1H),7.52(d,J=7.5Hz,1H),7.47–7.42(m,4H),7.43–7.36(m,2H),7.28(t,J=7.4Hz,4H),7.21(s,1H),6.65(d,J=7.5Hz,1H),4.13(t,J=5.0Hz,2H),3.94(s,3H),3.86(t,J=4.9Hz,2H),0.93(s,9H).
LCMS found:475[M+H]+。
Example 4: synthesis of 5- (2- ((tert-butyldiphenylsilyl) oxy) ethyl) -4-oxo-4, 5-dihydrofuran [3,2-c ] pyridine-2-carboxylic acid
The synthetic route is as follows:
step 1:
to a reaction flask were added compound 1(8.7g,56.7mmol,1.0eq), 30% MeONa-MeOH solution (40mL) in sequence; heating the outer bath to 75 ℃, and stirring; TLC monitoring reaction is completed; cooling, adding water, and extracting with ethyl acetate for 3 times; the organic phases were combined, washed 4 times with 15% saline and 1 time with saturated saline. Drying with anhydrous sodium sulfate; and (6) spin-drying. 7.6g of a yellow solid are obtained, yield 89.7%.
LCMS found:150[M+H]+
Step 2:
adding 2(7.6g,51.0mmol,1.0eq) into a reaction bottle in sequence, and newly steaming anhydrous THF under the protection of inert gas; cooling the dry ice-acetone to-78 ℃; n-BuLi (30.5mL,76.5mmol,1.5eq,2.5M) was added dropwise; stirring for 30min at low temperature; introducing carbon dioxide dried by concentrated sulfuric acid and anhydrous calcium chloride into the reaction solution; reacting for 3 hours, and slowly heating to 0 ℃ below zero; adding saturated solution of ammonium chloride for quenching; adding water and ethyl acetate; separating out an organic phase; the aqueous phase was washed once with ethyl acetate; adjusting the pH value of the water phase to 2; a large amount of solid was precipitated, filtered and dried to obtain 9.4g of solid with a yield of 95.5%.
1H NMR(400MHz,DMSO-d6)δ8.15(d,J=6.0Hz,1H),7.60(s,1H),7.39(dd,J=6.0,0.9Hz,1H),4.02(s,3H).
LCMS found:194[M+H]+
And step 3:
compound 3(9.0g, 46.6mmol, 1.0eq), ethanol (270mL) and concentrated sulfuric acid (11.5mL) were added to a reaction flask and heated to reflux; stirring overnight, evaporating ethanol, cooling the residue with ice water bath, and adding water dropwise to precipitate solid; filtration and drying gave 7.4g of solid in 76.7% yield.
1H NMR(400MHz,DMSO-d6)δ11.68(s,1H),7.61(d,J=2.3Hz,1H),7.50(d,J=7.5Hz,1H),6.73(d,J=7.4Hz,1H),4.33(q,J=7.1Hz,2H),1.31(td,J=7.1,2.9Hz,3H).
LCMS found:208[M+H]+
And 4, step 4:
4(7.0g, 33.8mmol, 1.0eq), 70mL DMAc, cesium carbonate (22.0g,67.5mmol,2.0eq) and compound 5(14.7g, 40.5mmol, 1.2eq) were added to a reaction flask, stirred at room temperature for 2h, water and ethyl acetate were added, ethyl acetate was separated, the aqueous phase was extracted once with ethyl acetate, the organic phases were combined, washed with saturated sodium chloride, and spin-dried to give compound 6, which was directly fed to the next step without purification.
LCMS found 490[M+H]+
And 5:
the crude compound 6 from the previous step, ethanol (70mL) and water (18mL) were added to the reaction flask and LiOH solid (1.22g, 20.9mmol, 1.5eq) was added. Stirring at room temperature for 0.5h, concentrating ethanol, and adding water and ethyl acetate to the residue; separating out ethyl acetate; water phase ice water bath, adjusting pH to 5, and separating out a large amount of solid; filtration and drying gave 10.3g of solid 7, yield 66.1% (two steps).
1H NMR(400MHz,DMSO-d6)δ7.82(d,J=7.5Hz,1H),7.54(d,J=0.9Hz,1H),7.48–7.34(m,7H),7.29(t,J=7.3Hz,4H),6.80(dd,J=7.5,0.9Hz,1H),4.19(t,J=4.9Hz,2H),3.88(t,J=4.9Hz,2H),0.92(s,9H).
LCMS found:462[M+H]+
Step 6: 2-amino-5- (2- ((tert-butyldiphenylsilyl) oxy) ethyl) furan [3,2-c ] pyrido-4 (5H) -one
Adding the compound 7(462mg, 1mmol) into anhydrous THF (5mL), then adding triethylamine (233mg, 2.3mmol) and azido diphenyl phosphate (316mg,1.15mmol), stirring at room temperature for 2h, then heating to reflux for 2h, then adding water (1.0mL), continuing to reflux for overnight, cooling, then adding EA for extraction, concentrating, and separating by column chromatography to obtain the product. LCMS found:462[ M + H ]]+
Example 5: synthesis of 5- (2- ((tert-butyldiphenylsilyl) oxy) ethyl) -7-cyano-1-methyl-4-oxo-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxylic acid
The synthetic route is as follows:
step 1:
adding 25g of the compound 1 into 75ml of methanol, cooling to 0 ℃, dropwise adding 62.89g of thionyl chloride, and heating to room temperature for reaction for 2d after dropwise adding; and (3) sampling LCMS, completely reacting the raw materials, evaporating most of methanol, pouring ice water into residues, extracting by EA, combining organic phases, washing with salt, drying and spin-drying to obtain 22.7g of crude products. The crude product is directly put into the next step.
Step 2:
adding 10.7g of compound 2 into 54ml of methanol, adding 14.6g of sodium methoxide/methanol (30% wt), and after the addition is finished, heating and refluxing overnight (the system turns turbid from clear); sample LCMS and starting material was essentially reacted to completion and worked up. The methanol was evaporated, the residual DCM diluted, washed with ice water, brine, dried and spin dried to give 8.9g of crude yellow solid. The crude product is directly put into the next step. Yield: 84.7 percent
Step 3
Cooling 180ml of anhydrous THF to below-10 ℃ under the protection of argon; adding 2.8g of LiAiH4 in portions; dissolving 8.9g of compound 3 in 50ml of THF, and dropwise adding at a temperature below-10 ℃; keeping the temperature for reaction for 30min after dripping, sampling LCMS, basically completely reacting the raw materials, controlling the temperature to be less than-10 ℃, stirring 3ml of water and anhydrous sodium sulfate into sand, and adding the sand in batches; after the addition, filtering, and washing a filter cake EA; the combined organic phases were washed with salt, dried overnight, spun dried, and applied to a column to yield 4.7g of white solids (15% EA in HEP). Yield: 59.5 percent
Step 4
Dissolving 3.5g of compound 4 in 70ml of DCM, adding 10.2g of dess-Martin in batches, and reacting for 2h at room temperature after the addition is finished (the system is white and turbid); sampling LCMS to show that the raw materials are basically reacted completely, pouring into a saturated aqueous solution of ice sodium bicarbonate and sodium thiosulfate (1: 1), and extracting the aqueous phase with DCM for 1 time; the combined organic phases were washed with saturated brine, dried, spun-dried and chromatographed to give 3.1g of a white solid. Yield: 90.6 percent
Step 5
Dissolving 4g of compound 5 in 40ml of methanol, and cooling to the temperature of minus 15 ℃ to minus 10 ℃ under the protection of argon; 4.8g of ethyl azidoacetate are added; controlling the temperature to be-15 to-10 ℃, and dropwise adding 10g of sodium methoxide/methanol (30 percent by weight); after dripping, the reaction is kept for 2h (the system is changed from clear to white and turbid); carrying out external bath at-10 ℃, and keeping the temperature to react overnight; sampling LCMS, pouring the raw materials into ice saturated ammonium chloride aqueous solution after the raw materials are basically completely reacted, filtering the solid, extracting the aqueous phase for 2 times by EA, combining the organic phase soluble solid, washing with salt, drying and spin-drying to obtain 6g of light yellow solid. The crude product is directly put into the next step. Yield: 97.8 percent
Step 6
Dissolving 10.1g of compound 6 in 300ml of THF (tetrahydrofuran), and cooling to-40 to-30 ℃ under the protection of argon; 7.0g of methanesulfonyl chloride was added; controlling the temperature to be between 40 ℃ below zero and 30 ℃ below zero, dripping 21.6g of triethylamine, and keeping the temperature to react for 1.5h (the system turns turbid from clear); sampling LCMS, pouring the residual 7 percent of the raw materials into ice water, EA extracting, combining organic phases, washing with salt, drying, spin-drying, mixing the sample and passing through a column to obtain 4.8g of light yellow solid (10 percent of EA in HEP product). Yield: 50.2 percent
Step 7
Dissolving 4.8g of compound 7 in 200ml of o-dichlorobenzene, heating to 140 ℃ under the protection of argon, and reacting for 1h (the system is clear); LCMS is sampled, the raw materials are reacted completely, and the dried o-dichlorobenzene is concentrated under reduced pressure by an oil pump. The crude product is directly put into the next step.
Step 8
Dissolving 4.37g of the compound 8 in 50ml of DMAc, adding 4.24g of potassium carbonate under the protection of argon, and dropwise adding 2.61g of methyl iodide at room temperature; after dripping, reacting at room temperature for 1 h; sample LCMS, the raw material reaction is complete, pour into ice ammonia water, EA extract, combine organic phase, salt wash, dry, spin dry, mix sample and get 4.7g light yellow solid. Yield: 100 percent
Step 9
Dissolving 2.8g of compound 9 in 33ml of acetic acid, adding 33ml of hydrobromic acid, and after the addition is finished, heating to 93 ℃ (external oil bath) for reaction for 1 h; sampling LCMS, cooling the residual 3 percent of the raw material and 20 percent of saponified acid to room temperature, and drying the raw material at 60 ℃ by an oil pump to obtain yellow solid; dissolving in 30ml methanol, dripping 3ml concentrated sulfuric acid, heating and refluxing, and monitoring by LCMS until the saponified acid content is less than 8 percent, then processing: most of the methanol is removed by rotation, EA is diluted, and the yellow solid crude product is obtained by salt washing, drying and rotary drying. Yield: 89.8 percent
Step 10
Dissolving 1.36g of compound 10 in 70ml of DMAc, adding 3.11g of cesium carbonate, adding 2.08g B, and reacting at room temperature for 3 hours after the addition is finished; sample LCMS and the material was essentially reacted completely, poured into ice water, extracted with 2-MeTHF, combined organic phases, washed with salt, dried, spun dry, and chromatographed on a column to give 2.4g of a pale yellow oil. Yield: 88.6 percent
Step 11
Dissolving 4.3g of compound 11 in 86ml of NMP, adding 2.0g of cuprous cyanide, and after the addition, heating to 170 ℃ (external oil bath) for reaction for 6 h; sampling LCMS, cooling the residual 3 percent of the raw materials to room temperature, pouring into ice water, extracting by EA, combining organic phases, washing by salt, drying, spin-drying, mixing the sample and passing through a column to obtain 1.8g of light yellow solid. Yield: 46.2 percent of
1H NMR(400MHz,CDCl3)δ7.77(s,1H),7.52(s,1H),7.51–7.47(m,4H),7.37–7.30(m,2H),7.28(dd,J=7.2,1.1Hz,4H),4.33(s,3H),4.13(dd,J=5.4,3.9Hz,2H),3.97(dd,J=5.4,3.9Hz,2H),3.91(s,3H),1.06(s,9H).
Step 12
Dissolving 1.7g of compound 12 in 17ml of THF, dissolving 0.4g of LiOH in 17ml of H2O, and dropwise adding the reaction solution to react for 1H at room temperature after dropwise adding; TLC was sampled, the starting material was reacted substantially completely, THF was spun off at room temperature, pH was adjusted to 1 with 2M aqueous hydrochloric acid in ice bath, stirring was carried out for 10min, the filter cake was washed with water, and 2g of crude pale yellow solid was obtained with water in toluene. Yield: 100 percent
Example 6: (R) -3- ((3- ((tert-butyldiphenylsilyl) oxy) pyrrol-1-yl) methyl) -8-chloro-1, 7-diazanaphthalene
The synthetic route is as follows:
step 1:
compound 1(21.8g,110.6mmol,1eq) was dissolved in TFA-H2SO4(4:1,350mL,16V) in the mixed solution, heating to 40 ℃, stirring overnight, taking a light yellow solution, sampling LCMS to show that the reaction is finished, concentrating the system, dripping the residue into ice water, separating out a large amount of colorless crystals, extracting IPAc once, adjusting the pH of an aqueous phase with 10M NaOH aqueous solution to 8-9, extracting the aqueous phase with IPAc three times again, combining all organic phases, washing with saturated sodium carbonate and saturated sodium chloride aqueous solution in sequence, drying with anhydrous sodium sulfate, filtering, concentrating, and obtaining a compound 2 which is a white crystal and 23.2g in total. The yield thereof was found to be 97.5%.
1H NMR(400MHz,DMSO-d6)δ8.54(d,J=2.1Hz,1H),8.05(d,J=2.1Hz,1H),7.96(s,1H),7.55(s,1H).,2.50(s,3H)
LCMS:found 215:217=1:1[M+H]+
The other method comprises the following steps:
mixing the compound 1-1(18.4g,85.2mmol,1eq) and thionyl chloride (180mL,10V) to form white turbidity, stirring and heating to reflux, changing the system into a yellow solution after about 1h, stopping heating and concentrating, adding THF (tetrahydrofuran) into the residue to dissolve, dropwise adding ammonia water into a 1, 4-dioxane solution (0.4M,178.9mL, 2.1eq) under ice bath, after dropwise adding, returning the system to room temperature and stirring for 30min, concentrating, adding water into the residue, extracting IOAc for three times, combining organic phases, washing with saturated saline, drying with anhydrous sodium sulfate, filtering the filtrate and concentrating to obtain 20.3g of a white foamy solid, and quantifying the yield.
Step 2:
compound 2(40.8g,189.7mmol,1eq) and DMF-DMA (33.9g,284.6mmol,1.5eq) were dissolved in toluene (612mL,15V), heated to reflux overnight with stirring, LCMS indicated complete consumption of starting material, concentrated under reduced pressure, and the residue was taken up in the next reaction without isolation.
LCMS:found 270:272=1:1[M+H]+
And step 3:
dissolving the compound 3(49.4g,182.9mmol,1eq) in tetrahydrofuran (1.5L, KF 0.05%, 30V 10mL/g), adding potassium tert-butoxide (30.8g,274.4mmol,1.5eq) after nitrogen replacement, stirring and heating to reflux after nitrogen replacement again, changing the system from reddish brown to brown black, cooling to room temperature, adding water to quench the reaction, adjusting the pH to 7-8 with hydrochloric acid, concentrating, extracting the residue with 2-methyltetrahydrofuran three times, combining organic phases, washing with saturated brine, drying with anhydrous sodium sulfate, filtering, concentrating the filtrate, and carrying out column chromatography on the residue to obtain 12g of the compound 4 which is yellow to reddish brown solid. The total yield of the two steps is 29 percent.
1H NMR(400MHz,DMSO-d6)δ11.63(s,1H),8.80(d,J=2.2Hz,1H),8.48(d,J=2.2Hz,1H),7.32(d,J=7.1Hz,1H),6.51(d,J=7.1Hz,1H).
LCMS:found 225:227=1:1[M+H]
And 4, step 4:
after compound 4(13.5g,60.0mmol,1eq) and phosphorus oxychloride (135mL,10V) were mixed, heated under reflux for 2h under stirring, LCMS showed the reaction was complete, concentrated, the residue was diluted with water, EA was added and slurried for 1h, filtered, the filter cake was washed with water and dried to give the product as a pale yellow solid, 9.6g, 65.7% yield.
1H NMR(400MHz,DMSO-d6)δ9.21(d,J=2.3Hz,1H),8.93(d,J=2.3Hz,1H),8.46(d,J=5.6Hz,1H),7.92(d,J=5.6Hz,1H).
LCMS:found 243:245:247=3:3:1[M+H]+.
And 5:
the starting material compound 5(9.6g,39.4mmol,1eq), vinyl boronic acid pinacol ester (6.68g,43.4mmol,1.1eq), sodium carbonate (20.9g,197.1mmol,5eq) were added to a THF-water (4:1,480mL,50V) mixed solvent, after nitrogen substitution, tetrakistriphenylphosphine palladium (911.2mg,0.79mmol,0.02eq) was added, after nitrogen substitution again, stirring was carried out to reflux, and after 1.5h, TLC and LCMS analysis of the remaining small amount of starting material. After stopping heating, the system was concentrated, and the residue was extracted three times with EA, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and subjected to column chromatography (EA in Hep 15%) to obtain the product compound 6 as a pale yellow solid 5.9g with a yield of 76.1%.
1H NMR(400MHz,DMSO-d6)δ9.31(d,J=2.2Hz,1H),8.50(d,J=2.2Hz,1H),8.38(d,J=5.5Hz,1H),7.89(d,J=5.5Hz,1H),7.00(dd,J=17.7,11.1Hz,1H),6.31(d,J=17.7Hz,1H),5.67(d,J=11.1Hz,1H).
LCMS:found 191/193=3:1[M+H]+
Step 6:
compound 6(4.0g,21.1mmol,1.0eq), NMO (4.9g,41.8mmol,2.0eq) and K were added in that order2OsO4(0.38g,1.03mmol,0.049eq) THF H was added2Stirring overnight at room temperature in solvent (100ml) of 3:1, monitoring reaction by TLC (PE: EA: 1) until the starting material point disappears, and adding aqueous solution of sodium sulfite to quench the reaction; extracting with ethyl acetate (4 times), mixing the organic phases, washing with saturated brine, spin-drying the solvent, and adding THF: H2Dissolving in solvent (3: 1) and adding NaIO4Solid (11.2g,52.4mmol,2.49eq), stirred, TLC monitored reaction was complete, water was added to dissolve the solid, extracted with ethyl acetate (4 times), the organic phases were combined, washed with saturated chloride, dried over anhydrous sodium sulfate, solvent was dried by rotary drying to give 3.45g of product 7 as a flocculent solid in 85.3% yield.
1H NMR(400MHz,DMSO-d6)δ10.32(s,1H),9.48(d,J=2.0Hz,1H),9.10(d,J=2.0Hz,1H),8.54(d,J=5.5Hz,1H),8.18(d,J=5.5Hz,1H).
LCMS found 193:195=3:1[M+H]
Step 7
Under nitrogen protection, compound 7(3.45g,17.9mmol,1.0eq), compound 8(6.5g,17.96mmol,1.0eq) and Et were added3N (7.35g,72.6mmol,4.1eq) was added to DCM (100ml), the temperature was reduced in an ice-water bath, after stirring for about 15min, NaBH (OAc)3(5.7g,26.9mmol,1.5eq) was added to a reaction flask, stirred in an ice water bath for-2 h and then warmed to room temperature and stirred overnight, TLC monitored reaction (DCM: MeOH ═ 20:1) was complete, quenched with aqueous sodium hydroxide solution, the organic phase separated, the aqueous phase extracted with DCM, combined organic phases and column purified to give the product as a light brown oily liquid, totaling 5.6 g; the yield thereof was found to be 62.3%.
1H NMR(400MHz,DMSO-d6)δ9.04(d,J=2.1Hz,1H),8.39(d,J=5.5Hz,1H),8.34(d,J=2.0Hz,1H),7.92(d,J=5.5Hz,1H),7.57(ddt,J=11.4,6.3,1.8Hz,4H),7.48–7.32(m,6H),4.37(dq,J=9.8,3.6Hz,1H),3.89(d,J=14.0Hz,1H),3.79(d,J=14.0Hz,1H),2.69(dt,J=9.8,6.6Hz,2H),1.95(dq,J=14.3,7.3Hz,1H),1.82–1.62(m,1H),1.23(dd,J=7.0,4.6Hz,2H),0.98(s,9H).
LCMS found 502:504=3:1[M+H]
Example 7: synthesis of (R) -3 ' - ((3- ((3- ((tert-butyldiphenylsilyl) oxy) pyrrol-1-yl) methyl) -1, 7-diazanaphthalen-8-yl) amino) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3-carboxylic acid
Step 1
Block 1(0.3g,0.6mmol,1.0eq), isopropanol, Compound 1(0.145g,0.6mmol,1.0eq) and TosOH-H were added to the reaction flask in this order2O (0.117g,0.61mmol,1.0eq), heated under reflux for 8h, monitored by TLC (HEP: EA: 3:1) until the starting material point disappeared, EA was added, the organic phase was washed with aqueous sodium bicarbonate, dried, and column chromatographed to give 0.287g of product in 67.8% yield.
LCMS found 721[M+H]
Step 2:
compound 2(287mg, 0.4mmol) was dissolved in THF/H2O (3:1, 3ml), adding LiOH (28.6mg, 1.2mmol), stirring at room temperature overnight, TLC monitoring reaction until the raw material point disappears, dropwise adding 1N hydrochloric acid to adjust pH to neutral, extracting with ethyl acetate, drying, separating by column chromatography to obtain 280mg of product, and quantifying yield.
LCMS found 707[M+H]
(R) -N- (3-bromo-2-methylphenyl) -3- ((3- ((tert-butyldiphenylsilyl) oxy) pyrrol-1-yl) methyl) -1, 7-diazanaphthalen-8-amine
Synthesized according to the method of step 1 of reference example 7.
(R) -N3- (3- ((3- ((tert-butyldiphenylsilyl) oxy) pyrrol-1-yl) methyl) -1, 7-diazanaphthalen-8-yl) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3,3 ' -diamine
Synthesized according to the method of step 1 of reference example 7.
Example 8: synthesis of N- (5- (((3S) -cyclopentyl) methyl) -1-methyl-4-oxo-4, 5-dihydro-1H-imidazo [4,5-c ] pyridin-2-yl) -3- ((7(((R) -3-hydroxypyrrolidin-1-yl) methyl) quinolin-4-yl) oxy) -2,2 ' -dimethyl- [1,1 ' -biphenyl ] -3,3 ' -dicarboxamide.
The synthetic route is as follows:
to a solution of (R) -3 ' - ((7- ((3-hydroxypyrrol-1-yl) methyl) quinolin-4-yl) oxy) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3-carboxylic acid (468mg, 1mmol) and 2-amino-5- (((3S) -3-hydroxycyclopentyl) methyl) -1-methyl-1, 5-dihydro-4H-imidazo [4,5-c ] pyridin-4-one (262mg, 1mmol) in DMF (3mL) at room temperature were added HATU (456mg) and DIEA (258 mg). The mixture was then heated to 50 ℃ and stirred overnight, then cooled to room temperature. The mixture was purified by prep-HPLC to give the product.
LCMS found 713.3[M+H]+
Example 9: synthesis of N, N '- (2, 2' -dimethyl- [1,1 '-diphenyl ] -3, 3' -diyl) bis (5- (2-hydroxyethyl) -1-methyl-4-oxo-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxamide).
Step 1:
200mg of Compound 1 are added to 5.6ml of toluene and 4.5ml of methanol, and a solution of trimethylsilylated diazomethane cyclohexane (2M) is added dropwise until the yellow colour does not disappear anymore (0.25 ml); after stirring for 1min, the reaction was quenched with acetic acid (0.2ml) and adjusted to pH 8 with aqueous sodium bicarbonate. Spin-drying the solvent; EA extraction, organic phase combination, salt washing, drying, spin-dry mixing and column chromatography to obtain 214mg of white solid. Yield: 100 percent
Step 2
Dissolving 300mg of compound 2 and 149mg of compound 3 in 15ml of THF, performing nitrogen protection, performing ice salt bath, dropwise adding 2.5ml (2M) of NaHMDS THF solution, performing heat preservation reaction for 20min, performing LCMS detection, adding water to quench the raw materials to perform reaction, performing EA extraction, combining organic phases, performing salt washing, drying, performing spin-drying mixing, and performing column chromatography to obtain 160mg of light yellow solid. Yield: 37.2 percent
Step 3
Dissolving 160mg of compound 4 in 2ml of methanol, adding 100mg of 10% Pd/C, introducing hydrogen, reacting at room temperature for 30min, sampling, detecting by TLC, completely reacting the raw materials, filtering to remove 10% Pd/C, and spin-drying to obtain 140mg of off-white solid crude product; the crude product is directly put into the next step. Yield: 91.5 percent
Step 4
Dissolving 55mg of compound 2 and 75mg of compound 5 in 3.8ml of THF, performing nitrogen protection, performing ice salt bath, dropwise adding 0.45ml of (2M) NaHMDS THF solution, and reacting for 1h under the condition of keeping temperature after dropwise adding; adding water to quench and react, extracting with EA, combining organic phases, washing with salt, drying, mixing with a rotary drying sample, and passing through a column to obtain 53mg yellow solid. Yield: 41.9 percent
Step 5
53mg of Compound 6 was dissolved in 2.5ml of THF, 2.5ml of triethylamine trihydrofluoride was added thereto, the mixture was reacted at room temperature for 2 hours, TLC was sampled, the reaction of the starting material was substantially completed (. about.30% of the product), THF was distilled off under reduced pressure, and preparative TLC separation was carried out to obtain 6.1mg of THF. Yield: 20.3 percent of
1H NMR(400MHz,DMSO-d6)δ9.85(s,1H),7.55(s,1H),7.43(d,J=7.5Hz,1H),7.39(d,J=7.9Hz,1H),7.30(t,J=7.8Hz,1H),7.02(d,J=7.4Hz,1H),6.62(d,J=7.5Hz,1H),4.00(t,J=5.7Hz,2H),3.95(s,3H),3.62(t,J=5.6Hz,2H),1.96(s,4H),1.24(s,1H).
Example 10: synthesis of (1r,4r) -4- ((2- ((2,2 ' -dimethyl-3 ' - (4-oxo-4, 5,6, 7-tetrahydrothiazolo [4,5-c ] pyridopyridin-2-yl) - [1,1 ' -diphenyl ] -3-yl) carbamoyl) -1-methyl-1, 4,6, 7-tetrahydro-5H-imidazo [4,5-c ] pyridopyridin-5-yl) methyl) cyclohexane-1-carboxylic acid.
The synthetic route is as follows:
step 1:
1(318mg) was dissolved in dioxane (15mL) at room temperature, and 2(323mg) and 1.5mL Na were added2CO3(2N) aqueous solution, vacuum degassing, then addition of Pd (dppf) Cl2(73.2mg), degassed again and reacted at 90 degrees overnight. After cooling to room temperature, the reaction was extracted with water and EtOAc, the organic phase was washed with saturated NaCl, dried, spun-dried and passed through a column (HEP: EtOAc: 5: 1-2: 1) to yield 150mg of a pale yellow solid.
Step 2:
compound 3(150mg) was dissolved in DMF (2ml) at room temperature, HATU (196.7mg) and DIEA (113mg) were added, and the mixture was stirred for 10 minutes, followed by addition of compound 4(138.7mg), and the reaction was continued at room temperature overnight. The reaction was extracted with water and EtOAc, the organic phase washed with saturated NaCl, dried, spun dried and column filtered (HEP: EtOAc ═ 5: 1-1: 1) to give 100mg of a pale yellow solid.
And step 3:
compound 5(100mg) was dissolved in 4N HCl/dioxane (2ml) at room temperature, stirred for 30 minutes, TLC detected disappearance of starting material and reaction was concentrated and used directly for the next reaction.
And 4, step 4:
compound 6(100mg, N) was dissolved in MeOH/H at room temperature2O (1ml,1:1), LiOH2O (12.2mg), and stirred for 2 hours. TLC detection is carried out, the pH value is adjusted to 6-7 by 1N HCl, and the organic phase is prepared into (1r,4r) -4- ((2- ((2,2 '-dimethyl-3' - (4-oxo-4, 5,6, 7-tetrahydrothiazole [4, 5-c) by high performance liquid chromatography]And pyridin-2-yl) - [1, 1' -Diphenyl]-3-yl) carbamoyl) -1-methyl-1, 4,6, 7-tetrahydro-5H-imidazole [4,5-c ]]And pyridin-5-yl) methyl) cyclohexane-1-carboxylic acid. LC-MS found 653.3(M + H)
Example 11: synthesis of (R) -5- (2-hydroxyethyl) -N- (3 ' - ((3- ((3-hydroxypyrrolin-1-yl) methyl) -1, 7-dinaphthalen-8-yl) amino) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3-yl) -1-methyl-4-oxo-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxamide
The synthetic route is as follows:
step 1:
compound 1(120mg) and compound 2(86.5mg) were dissolved in THF (2ml) under ice-bath, and N was added2A2M solution of NaHMDS (0.7mL THF) was added with protection and the ice bath was continued for 1 hour. TLC showed complete reaction of starting material, saturated NH was added4And quenching the reaction by using a Cl aqueous solution, extracting by using EA, and carrying out column chromatography separation to obtain 80mg of yellow solid.
Step 2:
compound 3(90mg) was added to a mixture of THF (1mL) and TEA/3HF (1mL) and reacted for 2 hours. TLC detection for disappearance of raw material, reaction liquid is added with saturated NaHCO3The aqueous solution was adjusted to pH 9, extracted with EtOAc, and lyophilized to afford a yellow solid, 12.4 mg.
1H NMR(400MHz,DMSO-d6)δ10.98(d,J=94.5Hz,1H),9.88(s,1H),9.09(s,1H),8.52(s,1H),8.18(d,J=8.3Hz,1H),8.05(d,J=5.9Hz,1H),7.56(s,1H),7.38(ddd,J=30.9,13.6,7.3Hz,4H),7.26–7.17(m,1H),7.08(t,J=6.5Hz,1H),6.97(d,J=7.6Hz,1H),6.62(d,J=7.4Hz,1H),4.67(s,2H),4.47(s,1H),4.01(s,2H),3.95(s,3H),3.71–3.60(m,4H),2.93(m,1H),2.34-2.32(s,1H),2.07(s,3H),2.00(s,3H),1.95-1.85(m,1H),1.21-1.15(m,3H).
LCMS found 658[M+H]+
Example 12: synthesis of (R) -7-cyano-5- (2-hydroxyethyl) -N- (3 ' - ((3- ((3-hydroxypyrrolin-1-yl) methyl) -1, 7-diazanaphthalin-8-yl) amino) -2,2 ' -dimethyl- [1,1 ' -diphenyl ] -3-yl) -1-methyl-4-oxo-4, 5-dihydro-1H-pyrrolo [3,2-c ] pyridine-2-carboxamide
The synthetic route is as follows:
step 1:
dissolving compound 1(300mg) in toluene (8.4 mL)/methanol (6.6mL) mixed solution at room temperature, adding 2M cyclohexane solution of trimethylsilyl diazomethane (1.08mL) dropwise until yellow color does not disappear, detecting by TLC that raw materials react completely, adding 0.3mL AcOH to quench reaction, adding saturated NaHCO3The pH was adjusted to 9, the solvent was evaporated under reduced pressure, extracted with EtOAc and passed through a column to give 240mg of a white solid
Step 2:
compound 3(136mg) and compound 4(150mg) were dissolved in THF (3mL) in an ice bath, and NaHMDS (2M in THF, 0.88mL) was added under the protection of N2 and the reaction was continued for 1 hour in an ice bath. TLC shows the reaction is complete, saturated NH4Cl is added to quench the reaction, EA extraction, column chromatography separation gives 80mg of a yellow solid.
And step 3:
compound 5(40mg) was dissolved in THF (0.5mL) at room temperature, and TBAF/THF (0.1mL) was added to react for 3 hours. TLC showed the starting material was reacted completely, the solvent was distilled off under reduced pressure and preparative isolation gave 6.3mg of a yellow solid.
1H NMR(400MHz,DMSO-d6)δ10.02(s,1H),9.31(s,1H),8.87(s,1H),8.43(d,J=8.3Hz,1H),8.34(s,1H),8.19(s,1H),8.06(d,J=5.7Hz,1H),7.61(s,1H),7.40(d,J=8.1Hz,1H),7.38–7.26(m,2H),7.18(d,J=5.8Hz,1H),7.09(d,J=7.5Hz,1H),6.88(d,J=7.6Hz,1H),6.64(s,1H),5.33(t,J=4.8Hz,1H),4.92(t,J=5.6Hz,1H),4.72(d,J=4.6Hz,1H),4.24(s,3H),4.07(d,J=5.7Hz,1H),3.83(d,J=10.4Hz,2H),3.65(d,J=5.7Hz,2H),2.74(d,J=6.1Hz,1H),2.68(s,1H),2.41(s,1H),2.10(s,3H),2.01-1.90(m,5H),1.46-1.40(m,2H).
LCMS found 683[M+H]+
Biological assay
Example A: PD-1/PD-L1 homogeneous time-resolved fluorescence (HTRF) binding assay
The assay was performed in standard black 384 well polystyrene plates with a final volume of 20. mu.L. Firstly, the methodInhibitors were serially diluted in DMSO and added to the plate wells, followed by the addition of the other reaction components. The final concentration of DMSO in the assay was 1%. The assay was performed in PBS buffer (pH7.4) containing 0.05% Tween-20 and 0.1% BSA at 25 ℃. Recombinant human PD-L1 protein (19-238) with a His tag at the C-terminus was purchased from Acro biosystems (PD 1-H5229). Recombinant human PD-1 protein (25-167) with an Fc marker at the C-terminus was also purchased from Acrobiosystems (PD 1-H5257). PD-L1 and PD-1 protein were diluted in assay buffer and 0.1. mu.l of the solution was extracted and added to the plate well. The plates were centrifuged and the proteins were preincubated with inhibitors for 40 minutes. After incubation, 0.1. mu.l of HTRF detection buffer containing europium-blocked labeled anti-human IgG (Perkinelmer-AD0212) Fc specific and anti-HisAllophycocyanin (APC, Perkinelmer-AD0059H) conjugated antibody. After centrifugation, the plates were incubated at 25 ℃ for 60 minutes. The data were read (665nm/620nm ratio) in a PHERAStar FS plate reader. The final concentrations in the assay were-3 nM PD1, 10nM PD-L1, 1nM europium anti-human IgG and 20nM anti-His-allophycocyanin. The activity data were fitted using GraphPad Prism 5.0 software to give IC50 values for the inhibitors.
The compound IC50 values illustrated in the examples are represented in the following manner: IC50 ≤ 100 nM; 100nM < IC50 ≦ 1000 nM; 1000nM < IC50 +++, and
data for the example compounds obtained using the PD-1/PD-L1 Homogeneous Time Resolved Fluorescence (HTRF) binding assay described in example a are provided in table 1.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (14)
1. A compound of formula I, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1、L2and L3Each independently selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO2;
Y1、Y2、Y3Each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO or SO2;
r is H, substituted or unsubstituted C1-C6Alkyl, substitutedOr unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent;
Each independently selected from the group consisting of: substituted or unsubstituted C6-C10 arylene, or substituted or unsubstituted 5-12 membered (preferably 5-7 membered) heteroarylene having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclylene, substituted or unsubstituted 5-12 membered C5-C12 cycloalkylene; or the saidIs absent;
R1、R2、R3and R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstitutedSubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclyl having 1-4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O.
3. The compound of claim 1, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein said compound isEach independently selected from the group consisting of: substituted or unsubstituted phenylene, substituted or unsubstituted 5-7 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted 5-7 membered heterocyclylene, substituted or unsubstituted C5-C7 cycloalkylene.
4. The compound of claim 1, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein said ring isHaving a substituent represented by formula IV below:
wherein, L is4Selected from the group consisting of: substituted or unsubstituted C1-C4 alkylene, -S-, -O-, -NRa-, -S (O) -, -S (O)2-; preferably a substituted or unsubstituted C1-C4 alkylene group;
selected from the group consisting of: a substituted or unsubstituted 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; preferably, saidIs a 5-7 membered nitrogen containing heterocyclic group;
R5selected from the group consisting of: substituted or unsubstituted C1-C6 alkyl, -CN, hydroxy, amino, carboxy; wherein, theThe substituents are selected from the group consisting of: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy.
5. The compound of claim 1, wherein the compound of formula I is selected from a compound of formula Ia, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted 5-to 12-membered heterocyclyl having 1 to 4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, ammoniaA group, C1-C6 alkylamino, carboxyl, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O;
preferably, the compound is selected from the following compounds 1-125:
6. the compound of claim 1, wherein the compound of formula I is selected from compounds of formula Ib, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independentlySelected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl having 1-3 heteroatomsA substituted or unsubstituted 5-12 membered heterocyclic group having 1-4 heteroatoms, a substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O;
preferably, the compound is selected from the group consisting of compounds 126-202:
7. the compound of claim 1, wherein the compound of formula I is selected from compounds of formula Ic, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl having 1-3 heteroatoms, substituted or unsubstituted 5-12 membered heterocyclic ring having 1-4 heteroatomsRadicals, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O;
preferably, the compound is selected from the group consisting of compounds 203-313;
8. the compound of claim 1, wherein the compound of formula I is selected from the group consisting of formulae Id-1 and Id-2, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1and L3Each independently selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2and Z3Each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1and Y2Each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2And R3Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted 5-to 12-membered heterocyclyl having 1 to 4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl, Br, -CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O;
preferably, the compound is selected from the group consisting of compounds 314-355:
9. the compound of claim 1, wherein the compound of formula I is selected from a compound of formula Ie, or an optical isomer, hydrate, solvate, or pharmaceutically acceptable salt thereof:
wherein n, m, p and q are each independently selected from 0, 1,2,3 or 4;
L1selected from the group consisting of: a bond, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-, substituted or unsubstituted-NHC (O) NH-, or,Substituted or unsubstitutedSubstituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
wherein,
Z1selected from the group consisting of: o, S, NRf, N-O-Rf; wherein, said Rf is selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted C6-C10Heteroaryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6An alkynyl group;
Z2、Z3、Z4each independently selected from the group consisting of: NH, N, CH2N-O, SO or SO 2;
Y1、Y2、Y3each independently selected from the group consisting of: CH. CH (CH)2NH, N-O, CH, O, S, SO, or SO 2;
r is H, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C6-C10Aryl, cyano, -C (═ O) -NRdRe, -C (═ O) -substituted or unsubstituted C1-C6Alkoxy, -C (═ O) -substituted or unsubstituted C1-C6Alkyl, -C (═ O) -substituted or unsubstituted C3-C10Cycloalkyl, -C (═ O) -substituted or unsubstituted C2-C6Alkenyl, -C (═ O) -substituted or unsubstituted C2-C6Alkynyl, or- (L)1a)r-(L2a)s-(L3a)s-, in which,
each L1aEach independently is a group selected from the group consisting of; chemical bond, substituted or unsubstituted C1-C7Alkylene, substituted or unsubstituted C2-C4 alkenylene, substituted or unsubstituted C2-C4 alkynylene, -S-, -O-, substituted or unsubstituted-NH-, -S (O)2-、
L2aSelected from the group consisting of: substituted or unsubstituted C6-C12 arylene, substituted or unsubstituted 5-12 membered heteroarylene having 1-3 heteroatoms, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 5-10 membered heterocyclylene having 1-3 heteroatoms;
L3aselected from the group consisting of: substituted or unsubstituted C1-C10 alkyl, C1-C10 aryl, -CN, hydroxy, amino, carboxy, -CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、
r is 1,2,3, 4,5, 6;
s is 0, 1,2 respectively;
rd, Re are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C10Cycloalkyl, substituted or unsubstituted C6-C10An aryl group;
selected from the group consisting of: substituted or unsubstituted 5-12 membered heteroaryl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstitutedUnsubstituted 5-12 membered heterocyclyl, substituted or unsubstituted 5-12 membered C5-C12 cyclyl, wherein said heterocyclyl has 1-3 heteroatoms; or the saidIs absent; or the saidIs equal to
R1、R2、R3And R4Each independently selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, oxo (i.e., ═ O), ═ NRf, -CN, hydroxy, NRdRe (e.g., amino), substituted or unsubstituted C1-C6 amine, substituted or unsubstituted- (C1-C6 alkylene) -NH- (C1-C6 alkylene), carboxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 12-membered heteroaryl having 1 to 3 heteroatoms, substituted or unsubstituted 5-to 12-membered heterocyclyl having 1 to 4 heteroatoms, substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedOr (L)1a)r-(L2a)s-(L3a)s-;
Unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen: including but not limited to-F, Cl,Br、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3Oxo, -CN, hydroxy, amino, C1-C6 alkylamino, carboxy, -NHAc, a group selected from the group consisting of unsubstituted or substituted with one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryl, C3-C8 cycloalkyl, halogenated C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O; the substituents are selected from the following group: halogen, hydroxy, carboxy, cyano, C1-C6 alkoxy, C1-C6 alkylamino;
in the formulae above, any of the heteroatoms is selected from the group consisting of: n, S and O;
preferably, the compound is selected from the group consisting of compounds 356-360:
10. a process for the preparation of a compound of formula I according to claim 1, comprising a step selected from the group consisting of schemes 1,2 and 3:
synthesis scheme 1
(a) Taking halide 1-1 and appropriate coupling reagent 1-2 (such as boric acid, boric acid ester, tin reagent or Grignard reagent) as basic raw materials, and obtaining an intermediate compound 1-3 through coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(b) taking the intermediate 1-3 as a raw material, and reacting with carboxylic acid 1-4 under the action of a condensing agent (such as HATU, EDCI or HBTU) to obtain an amide intermediate 1-5;
(c) taking the intermediate 1-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 1-6;
(d) taking the intermediate 1-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
synthesis scheme 2:
(a) carboxylic ester 22-1 is taken as a raw material, and is subjected to aminolysis reaction with amine 2-2 under the catalysis of Lewis acid to obtain an intermediate compound 2-3;
(b) taking the intermediate 2-3 and a proper coupling reagent 2-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 2-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(c) taking the intermediate 2-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 2-6;
(d) taking the intermediate 2-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
synthesis scheme 3:
(a) using carboxylic ester 3-1 as a raw material, and carrying out Buchwald-Hartwig coupling or Ullmann coupling with amine 3-2 under the catalysis of palladium or copper to obtain an intermediate compound 3-3;
(b) taking the intermediate 3-3 and a proper coupling reagent 3-4 (such as boric acid, boric acid ester, a tin reagent or a Grignard reagent) as basic raw materials, and obtaining an intermediate compound 3-5 through a coupling reaction (such as Suzuki, Stille or Kumada coupling) catalyzed by palladium or copper;
(c) taking the intermediate 3-5 as a raw material, and removing a protecting group (Boc) under an acidic condition to obtain an intermediate 3-6;
(d) taking the intermediate 3-6 as a raw material, and carrying out nucleophilic substitution reaction with a halide under an alkaline condition, or carrying out reductive amination reaction with aldehyde or ketone under the action of a reducing agent to obtain a target compound I;
11. A pharmaceutical composition comprising (1) a compound of claim 1 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; (2) a pharmaceutically acceptable carrier.
12. Use of a compound according to claim 1 or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 7, for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases associated with the activity or expression of PD-1/PD-L1.
13. A PD-1/PD-L1 inhibitor, wherein said inhibitor comprises a compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
14. A method of inhibiting the PD-1/PD-L1 interaction in vitro comprising the steps of: contacting a compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, with PD-L1 protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811191323.8A CN111039942B (en) | 2018-10-12 | 2018-10-12 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811191323.8A CN111039942B (en) | 2018-10-12 | 2018-10-12 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111039942A true CN111039942A (en) | 2020-04-21 |
CN111039942B CN111039942B (en) | 2023-04-14 |
Family
ID=70229940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811191323.8A Active CN111039942B (en) | 2018-10-12 | 2018-10-12 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111039942B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112457331A (en) * | 2019-09-09 | 2021-03-09 | 上海长森药业有限公司 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
WO2021047555A1 (en) * | 2019-09-09 | 2021-03-18 | 上海长森药业有限公司 | Preparation of aromatic heterocyclic derivative as immunomodulator and application thereof |
WO2021136354A1 (en) * | 2020-01-03 | 2021-07-08 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method therefor and use thereof |
WO2021139647A1 (en) * | 2020-01-07 | 2021-07-15 | 上海和誉生物医药科技有限公司 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof |
WO2021147940A1 (en) * | 2020-01-21 | 2021-07-29 | 上海华汇拓医药科技有限公司 | Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof |
CN113637013A (en) * | 2020-05-11 | 2021-11-12 | 上海长森药业有限公司 | Preparation and application of biaryl ring linked aromatic heterocyclic derivative as immunomodulator |
WO2021254005A1 (en) * | 2020-06-17 | 2021-12-23 | 上海和誉生物医药科技有限公司 | Immunosuppressant, and preparation method therefor and use thereof |
WO2022089511A1 (en) * | 2020-10-29 | 2022-05-05 | 深圳微芯生物科技股份有限公司 | Biphenyl compound as immunomodulator, preparation method therefor and application thereof |
WO2022152316A1 (en) * | 2021-01-18 | 2022-07-21 | 南京明德新药研发有限公司 | Biphenyl derivative and use thereof |
CN115286598A (en) * | 2022-07-01 | 2022-11-04 | 中国石油化工股份有限公司 | Synthesis method of 2, 5-furan dicarboxylic acid diester compound |
WO2023019430A1 (en) * | 2021-08-17 | 2023-02-23 | Ascletis Bioscience Co., Ltd. | Compounds as immunomodulators of pd-l1 interactions |
US11760764B2 (en) | 2020-05-22 | 2023-09-19 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
US11897871B1 (en) | 2021-06-14 | 2024-02-13 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
US11952374B2 (en) | 2020-10-21 | 2024-04-09 | Aligos Therapeutics, Inc. | Bicyclic compounds |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119266A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
WO2018119236A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119224A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
-
2018
- 2018-10-12 CN CN201811191323.8A patent/CN111039942B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119266A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
WO2018119236A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119224A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112457331A (en) * | 2019-09-09 | 2021-03-09 | 上海长森药业有限公司 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
WO2021047556A1 (en) * | 2019-09-09 | 2021-03-18 | 上海长森药业有限公司 | Nitrogen-containing heterocyclic compound, and preparation method therefor, pharmaceutical composition comprising same and use thereof |
WO2021047555A1 (en) * | 2019-09-09 | 2021-03-18 | 上海长森药业有限公司 | Preparation of aromatic heterocyclic derivative as immunomodulator and application thereof |
CN114364683A (en) * | 2019-09-09 | 2022-04-15 | 上海长森药业有限公司 | Preparation and application of aromatic heterocyclic derivative as immunomodulator |
CN114364685A (en) * | 2019-09-09 | 2022-04-15 | 上海长森药业有限公司 | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof |
WO2021136354A1 (en) * | 2020-01-03 | 2021-07-08 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method therefor and use thereof |
CN113348170A (en) * | 2020-01-03 | 2021-09-03 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method and application thereof |
CN113348170B (en) * | 2020-01-03 | 2023-12-22 | 上海翰森生物医药科技有限公司 | Biphenyl derivative inhibitor, preparation method and application thereof |
WO2021139647A1 (en) * | 2020-01-07 | 2021-07-15 | 上海和誉生物医药科技有限公司 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof |
CN114502556B (en) * | 2020-01-07 | 2023-07-28 | 上海和誉生物医药科技有限公司 | Biphenyl fluoro double bond derivative, preparation method thereof and application thereof in pharmacy |
CN114502556A (en) * | 2020-01-07 | 2022-05-13 | 上海和誉生物医药科技有限公司 | Biphenyl fluoro double bond derivative and preparation method and pharmaceutical application thereof |
WO2021147940A1 (en) * | 2020-01-21 | 2021-07-29 | 上海华汇拓医药科技有限公司 | Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof |
CN114650993A (en) * | 2020-01-21 | 2022-06-21 | 上海华汇拓医药科技有限公司 | PD-1/PD-L1 inhibitor and preparation method and application thereof |
CN113637013A (en) * | 2020-05-11 | 2021-11-12 | 上海长森药业有限公司 | Preparation and application of biaryl ring linked aromatic heterocyclic derivative as immunomodulator |
US11760764B2 (en) | 2020-05-22 | 2023-09-19 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
TWI781607B (en) * | 2020-06-17 | 2022-10-21 | 大陸商上海和譽生物醫藥科技有限公司 | A kind of immunosuppressant, its preparation method and application |
WO2021254005A1 (en) * | 2020-06-17 | 2021-12-23 | 上海和誉生物医药科技有限公司 | Immunosuppressant, and preparation method therefor and use thereof |
US11952374B2 (en) | 2020-10-21 | 2024-04-09 | Aligos Therapeutics, Inc. | Bicyclic compounds |
US11866452B2 (en) | 2020-10-29 | 2024-01-09 | Shenzhen Chipscreen Biosciences Co., Ltd. | Biphenyl compound as immunomodulator, preparation method therefor and application thereof |
CN114698376A (en) * | 2020-10-29 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | Biphenyl compound as immunomodulator, and preparation method and application thereof |
WO2022089511A1 (en) * | 2020-10-29 | 2022-05-05 | 深圳微芯生物科技股份有限公司 | Biphenyl compound as immunomodulator, preparation method therefor and application thereof |
WO2022152316A1 (en) * | 2021-01-18 | 2022-07-21 | 南京明德新药研发有限公司 | Biphenyl derivative and use thereof |
US11897871B1 (en) | 2021-06-14 | 2024-02-13 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
US12084434B2 (en) | 2021-06-14 | 2024-09-10 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2023019430A1 (en) * | 2021-08-17 | 2023-02-23 | Ascletis Bioscience Co., Ltd. | Compounds as immunomodulators of pd-l1 interactions |
CN115286598A (en) * | 2022-07-01 | 2022-11-04 | 中国石油化工股份有限公司 | Synthesis method of 2, 5-furan dicarboxylic acid diester compound |
CN115286598B (en) * | 2022-07-01 | 2024-04-26 | 中国石油化工股份有限公司 | Synthesis method of 2, 5-furandicarboxylic acid diester compound |
Also Published As
Publication number | Publication date |
---|---|
CN111039942B (en) | 2023-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111039942B (en) | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | |
CN115135315A (en) | SOS1 inhibitors | |
CN104860931A (en) | Hepatitis C virus inhibitors and pharmaceutical uses thereof | |
CN114364676B (en) | Novel tricyclic aromatic heterocyclic compound, preparation method, pharmaceutical composition and application thereof | |
CN114364685A (en) | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | |
CN111163766A (en) | AHR inhibitors and uses thereof | |
CN113637013A (en) | Preparation and application of biaryl ring linked aromatic heterocyclic derivative as immunomodulator | |
KR20170075756A (en) | Carbazole derivatives | |
AU2020346172B2 (en) | Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof | |
CN110156656B (en) | Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application | |
CN114364683A (en) | Preparation and application of aromatic heterocyclic derivative as immunomodulator | |
CN108084172A (en) | Anti- hepatitis C virus compound | |
CN113717165A (en) | Novel tricyclic aromatic heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | |
CN113248492B (en) | Heterocycle substituted nitrogen-containing six-membered heterocyclic derivative, preparation method and medical application thereof | |
WO2012008508A1 (en) | Heterocyclic ring compound | |
JP7414550B2 (en) | (Hetero)arylimidazolone compounds | |
CN113121393B (en) | Aromatic amide compound and application thereof in medicines | |
WO2024125662A1 (en) | Preparation and application of novel biaryl ring compound as immunomodulator | |
CN111902401A (en) | Receptor inhibitors, pharmaceutical compositions comprising the same and uses thereof | |
WO2019120256A1 (en) | Five-membered heteroaryl ring derivative, pharmaceutical composition containing same, and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |